L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2001 ACS
AN 2001:208277 CAPLUS
DN 134:237495
TI Preparation of heteroaromatic amines as protein kinase inhibitors
IN Hirst, Gavin C.
PA BASF A.-G., Germany
SO PCT Int. Appl., 140 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001019828	A2	20010322	WO 2000-US25357	20000915
WO 2001019828	A3	20011004		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-154618 P 19990917
OS MARPAT 134:237495
GI



I

AB Two title compd., e.g., I, were prepd. as protein kinase inhibitors (no data). Thus, NCCH2NHC6H4(OPh)-4 was cyclocondensed with .alpha.-formylcyclopentaneacetonitrile (prepn. each given) and the product cyclocondensed with HC(:NH)NH2.HOAc to give I.

IT **330666-31-4P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP(Preparation); USES (Uses)(prepn. of heteroarom. amines as protein kinase inhibitors)

RN 330666-31-4 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-cyclopentyl-5-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)


OPh
H2N
N
N
N

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2001 ACS
AN 1998:42401 CAPLUS
DN 128:102099
TI Substituted 7-aminopyrrolo[3,2-d]pyrimidines and their use as inhibitors of tyrosine protein kinase pp60c-src
IN Altmann, Eva; Missbach, Martin; Widler, Leo; Maibaum, Jurgen Klaus
PA Novartis A.-G., Switz.; Altmann, Eva; Missbach, Martin; Widler, Leo; Maibaum, Jurgen Klaus
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9749706	A1	19971231	WO 1997-EP3115	19970616
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9731762	A1	19980114	AU 1997-31762	19970616
PRAI CH 1996-1591		19960625		
WO 1997-EP3115		19970616		

OS MARPAT 128:102099
GI



I

AB Pyrrolo[3,2-d]pyrimidines I [R1, R3 = (un)substituted or hetero-substituted alkyl, cyclohydrocarbyl, aryl, arylalkyl, heterocyclyl, or heterocyclylalkyl; R2 = H, alkyl, halo] and salts are described. The compds. have valuable pharmaceutical properties, and are effective esp. as tyrosine protein kinase inhibitors. They can be used in warm-blooded animals in the treatment of bone diseases and other diseases that are favorably influenced by inhibition of tyrosine protein kinase. Over 100 compds. were prepd. and/or claimed. For instance, Et 3-amino-4-phenyl-1H-pyrrole-2-carboxylate (prepn. given) underwent N-(dimethylamino)methylenation, cyclocondensation with NH3 to give a pyrrolopyrimidinone, conversion of oxo to chloro, N-alkylation with iso-PrBr, and ammonolysis of the chloride, to give title compd. I [R1 = iso-Pr, R2 = H, R3 = Ph]. At concns. of 0.001-10 .mu.M in vitro, I inhibited tyrosine protein kinase pp60c-src. I also gave partial to complete inhibition of bone loss, when administered in the Hock model (ovariectomized rat) at 1-100 mg/kg/day orally.
IT **201465-60-3P 201465-61-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(intermediate; prepn. of substituted aminopyrrolopyrimidines as tyrosine protein kinase inhibitors)
RN 201465-60-3 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[4-(2-iodoethoxy)phenyl]-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 201465-61-4 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[4-(2-chloroethoxy)phenyl]-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



IT **201464-34-8P 201464-85-9P 201464-86-0P**
201464-87-1P 201464-88-2P 201464-89-3P
201464-93-9P 201464-95-1P
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted aminopyrrolopyrimidines as tyrosine protein kinase inhibitors)

RN 201464-34-8 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(1-cyclohexen-1-yl)-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 201464-85-9 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(1-cyclopenten-1-yl)-5-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 201464-86-0 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(1-cyclopenten-1-yl)-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 201464-87-1 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(1-cyclopenten-1-yl)-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 201464-88-2 CAPLUS
CN Phenol, 3-[4-amino-7-(1-cyclopenten-1-yl)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]-(9CI) (CA INDEX NAME)



RN 201464-89-3 CAPLUS
CN Phenol, 4-[4-amino-7-(1-cyclopenten-1-yl)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]-(9CI) (CA INDEX NAME)



RN 201464-93-9 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-(3-methoxyphenyl)-7-(1-methylethyl)-(9CI) (CA INDEX NAME)



RN 201464-95-1 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(3-cyclopenten-1-yl)-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



IT **201464-25-7P 201464-27-9P 201464-28-0P**
201464-29-1P 201464-30-4P 201464-31-5P
201464-32-6P 201464-33-7P 201464-35-9P
201464-36-0P 201464-37-1P 201464-38-2P
201464-39-3P 201464-40-6P 201464-41-7P
201464-42-8P 201464-43-9P 201464-44-0P
201464-45-1P 201464-46-2P 201464-47-3P
201464-48-4P 201464-49-5P 201464-50-8P
201464-51-9P 201464-52-0P 201464-53-1P
201464-54-2P 201464-55-3P 201464-56-4P
201464-57-5P 201464-58-6P 201464-59-7P
201464-60-0P 201464-61-1P 201464-62-2P
201464-63-3P 201464-64-4P 201464-65-5P
201464-66-6P 201464-67-7P 201464-68-8P
201464-69-9P 201464-70-2P 201464-71-3P
201464-72-4P 201464-73-5P 201464-74-6P
201464-75-7P 201464-76-8P 201464-77-9P
201464-79-1P 201464-80-4P 201464-81-5P
201464-82-6P 201464-83-7P 201464-84-8P
201464-90-6P 201464-91-7P 201464-92-8P
201464-94-0P 201464-96-2P 201464-97-3P
201464-98-4P 201464-99-5P 201465-00-1P
201465-01-2P 201465-02-3P 201465-03-4P
201465-04-5P 201465-05-6P 201465-06-7P
201465-07-8P 201465-08-9P 201465-09-0P
201465-10-3P 201465-11-4P 201465-12-5P
201465-13-6P 201465-14-7P 201465-15-8P
201465-16-9P 201465-17-0P 201465-18-1P
201465-19-2P 201465-20-5P 201465-21-6P
201465-22-7P 201465-23-8P 201465-24-9P
201465-25-0P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of substituted aminopyrrolopyrimidines as tyrosine protein kinase inhibitors)

RN 201464-25-7 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5,7-diphenyl- (9CI) (CA INDEX NAME)



RN 201464-27-9 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-(4-methoxyphenyl)-7-phenyl- (9CI) (CA INDEX NAME)



RN 201464-28-0 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-(3-methoxyphenyl)-7-phenyl- (9CI) (CA INDEX NAME)



RN 201464-29-1 CAPLUS

CN Phenol, 4-(4-amino-7-phenyl-5H-pyrrolo[3,2-d]pyrimidin-5-yl)- (9CI) (CA INDEX NAME)



RN 201464-30-4 CAPLUS

CN Phenol, 3-(4-amino-7-phenyl-5H-pyrrolo[3,2-d]pyrimidin-5-yl)- (9CI) (CA INDEX NAME)



RN 201464-31-5 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-phenyl-7-[4-[2-(phenylmethoxy)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 201464-32-6 CAPLUS
CN Ethanol, 2-[4-(4-amino-5-phenyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenoxy]-
(9CI) (CA INDEX NAME)



RN 201464-33-7 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[4-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-5-phenyl- (9CI) (CA INDEX NAME)



RN 201464-35-9 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-cyclohexyl-5-(3-methoxyphenyl)-
(9CI) (CA INDEX NAME)



RN 201464-36-0 CAPLUS
CN Phenol, 3-[4-amino-7-(1-cyclohexen-1-yl)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]-
(9CI) (CA INDEX NAME)



RN 201464-37-1 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-phenyl-7-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 201464-38-2 CAPLUS
CN Phenol, 4-[4-amino-7-[4-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-5H-pyrrolo[3,2-
d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



RN 201464-39-3 CAPLUS
CN Phenol, 3-[4-amino-7-[4-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-5H-pyrrolo[3,2-

d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



RN 201464-40-6 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[4-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 201464-41-7 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[4-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 201464-42-8 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[4-(2-aminoethoxy)phenyl]-5-phenyl-
(9CI) (CA INDEX NAME)



RN 201464-43-9 CAPLUS
CN Phenol, 4-[4-amino-7-[4-(2-aminoethoxy)phenyl]-5H-pyrrolo[3,2-d]pyrimidin-

5-yl]- (9CI) (CA INDEX NAME)



RN 201464-44-0 CAPLUS
CN Phenol, 3-[4-amino-7-[4-(2-aminoethoxy)phenyl]-5H-pyrrolo[3,2-d]pyrimidin-
5-yl]- (9CI) (CA INDEX NAME)



RN 201464-45-1 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[4-(2-aminoethoxy)phenyl]-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 201464-46-2 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[4-(2-aminoethoxy)phenyl]-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 201464-47-3 CAPLUS
CN Ethanol, 2-[[2-[4-(4-amino-5-phenyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenoxy]ethyl]amino]- (9CI) (CA INDEX NAME)



RN 201464-48-4 CAPLUS
CN Phenol, 4-[4-amino-7-[4-[2-[(2-hydroxyethyl)amino]ethoxy]phenyl]-5H-pyrrolo[3,2-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



RN 201464-49-5 CAPLUS
CN Phenol, 3-[4-amino-7-[4-[2-[(2-hydroxyethyl)amino]ethoxy]phenyl]-5H-pyrrolo[3,2-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



RN 201464-50-8 CAPLUS
CN Ethanol, 2-[[2-[4-[4-amino-5-(4-methoxyphenyl)-5H-pyrrolo[3,2-d]pyrimidin-
7-yl]phenoxy]ethyl]amino]- (9CI) (CA INDEX NAME)



RN 201464-51-9 CAPLUS
CN Ethanol, 2-[[2-[4-[4-amino-5-(3-methoxyphenyl)-5H-pyrrolo[3,2-d]pyrimidin-
7-yl]phenoxy]ethyl]amino]- (9CI) (CA INDEX NAME)



RN 201464-52-0 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(1-cyclohexen-1-yl)-5-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 201464-53-1 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-cyclopentyl-5-phenyl- (9CI) (CA INDEX NAME)



RN 201464-54-2 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(1-cyclopenten-1-yl)-5-phenyl-(9CI)
(CA INDEX NAME)



RN 201464-55-3 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(3-cyclopenten-1-yl)-5-phenyl-(9CI)
(CA INDEX NAME)



RN 201464-56-4 CAPLUS
CN Cyclopentanol, 3-(4-amino-5-phenyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-(9CI)
(CA INDEX NAME)



RN 201464-57-5 CAPLUS
CN 2-Cyclopenten-1-ol, 3-(4-amino-5-phenyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-
(9CI) (CA INDEX NAME)



RN 201464-58-6 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(3-methoxycyclopentyl)-5-phenyl-
(9CI) (CA INDEX NAME)



RN 201464-59-7 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(3-methoxy-1-cyclopenten-1-yl)-5-
phenyl- (9CI) (CA INDEX NAME)



RN 201464-60-0 CAPLUS
CN Cyclopentanemethanol, 3-(4-amino-5-phenyl-5H-pyrrolo[3,2-d]pyrimidin-7-
yl)-
(9CI) (CA INDEX NAME)



RN 201464-61-1 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[3-(methoxymethyl)cyclopentyl]-5-
phenyl- (9CI) (CA INDEX NAME)



RN 201464-62-2 CAPLUS
CN 1,2-Cyclopentanediol, 4-(4-amino-5-phenyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-
(9CI) (CA INDEX NAME)



RN 201464-63-3 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(3-fluorocyclopentyl)-5-phenyl-
(9CI) (CA INDEX NAME)



RN 201464-64-4 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(3,4-difluorocyclopentyl)-5-phenyl-
(9CI) (CA INDEX NAME)



RN 201464-65-5 CAPLUS
CN Cyclohexanol, 3-(4-amino-5-phenyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-
(9CI)
(CA INDEX NAME)



RN 201464-66-6 CAPLUS

CN 2-Cyclohexen-1-ol, 3-(4-amino-5-phenyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-
(9CI) (CA INDEX NAME)



RN 201464-67-7 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(3-methoxycyclohexyl)-5-phenyl-
(9CI) (CA INDEX NAME)



RN 201464-68-8 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[3-(methoxymethyl)cyclohexyl]-5-
phenyl- (9CI) (CA INDEX NAME)



RN 201464-69-9 CAPLUS
CN Cyclohexanol, 4-(4-amino-5-phenyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-
(9CI)
(CA INDEX NAME)



RN 201464-70-2 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(4-methoxycyclohexyl)-5-phenyl-
(9CI) (CA INDEX NAME)



RN 201464-71-3 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[4-(methoxymethyl)cyclohexyl]-5-phenyl- (9CI) (CA INDEX NAME)



RN 201464-72-4 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-phenyl-7-(3-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 201464-73-5 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(1-methyl-3-piperidinyl)-5-phenyl- (9CI) (CA INDEX NAME)



RN 201464-74-6 CAPLUS
CN Pyrrolidine, 1-acetyl-3-(4-amino-5-phenyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-
(9CI) (CA INDEX NAME)



RN 201464-75-7 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-phenyl-7-(3-piperidinyl)- (9CI) (CA
INDEX NAME)



RN 201464-76-8 CAPLUS
CN Piperidine, 1-acetyl-3-(4-amino-5-phenyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-
(9CI) (CA INDEX NAME)



RN 201464-77-9 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-phenyl-7-(4-piperidinyl)- (9CI) (CA
INDEX NAME)



RN 201464-79-1 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(1-methyl-4-piperidinyl)-5-phenyl-
(9CI) (CA INDEX NAME)



RN 201464-80-4 CAPLUS
CN Piperidine, 1-acetyl-4-(4-amino-5-phenyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-

(9CI) (CA INDEX NAME)



RN 201464-81-5 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[5-(methoxymethyl)-3-pyrrolidinyl]-5-phenyl- (9CI) (CA INDEX NAME)



RN 201464-82-6 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-phenyl-7-(tetrahydro-3-furanyl)- (9CI) (CA INDEX NAME)



RN 201464-83-7 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-phenyl-7-(tetrahydro-3-thienyl)- (9CI) (CA INDEX NAME)



RN 201464-84-8 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-phenyl-7-(tetrahydro-1,1-dioxido-3-thienyl)- (9CI) (CA INDEX NAME)



RN 201464-90-6 CAPLUS
CN Phenol, 4-(4-amino-7-cyclopentyl-5H-pyrrolo[3,2-d]pyrimidin-5-yl)- (9CI) (CA INDEX NAME)



RN 201464-91-7 CAPLUS
CN Phenol, 3-(4-amino-7-cyclopentyl-5H-pyrrolo[3,2-d]pyrimidin-5-yl)- (9CI) (CA INDEX NAME)



RN 201464-92-8 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-cyclopentyl-5-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 201464-94-0 CAPLUS
CN Phenol, 3-[4-amino-7-(1-methylethyl)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



RN 201464-96-2 CAPLUS
CN Phenol, 3-[4-amino-7-(3-cyclopenten-1-yl)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]-
(9CI) (CA INDEX NAME)



RN 201464-97-3 CAPLUS
CN Phenol, 3-(4-amino-7-cyclohexyl-5H-pyrrolo[3,2-d]pyrimidin-5-yl)- (9CI)
(CA INDEX NAME)



RN 201464-98-4 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-cyclopentyl-5-(3-methoxyphenyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



RN 201464-99-5 CAPLUS

CN Ethanol, 2-[[2-[4-[4-amino-5-(3-methoxyphenyl)-5H-pyrrolo[3,2-d]pyrimidin-
7-yl]phenoxy]ethyl]methylamino]- (9CI) (CA INDEX NAME)



RN 201465-00-1 CAPLUS
CN Ethanol, 2-[4-[4-amino-5-(3-methoxyphenyl)-5H-pyrrolo[3,2-d]pyrimidin-7-yl]phenoxy]- (9CI) (CA INDEX NAME)



RN 201465-01-2 CAPLUS
CN Phenol, 3-[4-amino-7-[4-(2-hydroxyethoxy)phenyl]-5H-pyrrolo[3,2-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



RN 201465-02-3 CAPLUS
CN Ethanol, 2-[4-[4-amino-5-(3-methoxyphenyl)-5H-pyrrolo[3,2-d]pyrimidin-7-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 201465-03-4 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[4-[2-[(2-methoxyethyl)amino]ethoxy]phenyl]-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 201465-04-5 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-(3-methoxyphenyl)-7-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 201465-05-6 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[4-[2-[[(4-fluorophenyl)methyl]amino]ethoxy]phenyl]-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 201465-06-7 CAPLUS
CN Cyclohexanol, 4-[[2-[4-[4-amino-5-(3-methoxyphenyl)-5H-pyrrolo[3,2-d]pyrimidin-7-yl]phenoxy]ethyl]amino]- (9CI) (CA INDEX NAME)



RN 201465-07-8 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-(3-methoxyphenyl)-7-[4-[2-(1-piperazinyl)ethoxy]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



RN 201465-08-9 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[4-[2-(dimethylamino)ethoxy]phenyl]-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 201465-09-0 CAPLUS

CN 3-Pyrrolidinol, 1-[2-[4-[4-amino-5-(3-methoxyphenyl)-5H-pyrrolo[3,2-d]pyrimidin-7-yl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 201465-10-3 CAPLUS
CN Ethanol, 2-[4-[4-amino-5-(3-fluorophenyl)-5H-pyrrolo[3,2-d]pyrimidin-7-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 201465-11-4 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[4-(2-aminoethoxy)phenyl]-5-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 201465-12-5 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-(3-fluorophenyl)-7-[4-[2-[(2-methoxyethyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 201465-13-6 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-(3-fluorophenyl)-7-[4-[2-[(2-methoxyethyl)methylamino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 201465-14-7 CAPLUS
CN Ethanol, 2-[[2-[4-[4-amino-5-(3-fluorophenyl)-5H-pyrrolo[3,2-d]pyrimidin-7-yl]phenoxy]ethyl]amino]- (9CI) (CA INDEX NAME)



RN 201465-15-8 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-(3-fluorophenyl)-7-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 201465-16-9 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-(3-fluorophenyl)-7-[4-[2-(1-piperazinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 201465-17-0 CAPLUS
CN Phenol, 3-[4-amino-7-(4-hydroxyphenyl)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



RN 201465-18-1 CAPLUS
CN Phenol, 3-[4-amino-7-[4-[2-[(2-hydroxyethyl)methylamino]ethoxy]phenyl]-5H-
pyrrolo[3,2-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



RN 201465-19-2 CAPLUS
CN Phenol, 3-[4-amino-7-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-5H-pyrrolo[3,2-
d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



RN 201465-20-5 CAPLUS
CN 3-Pyrrolidinol, 1-[2-[4-[4-amino-5-(3-hydroxyphenyl)-5H-pyrrolo[3,2-
d]pyrimidin-7-yl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 201465-21-6 CAPLUS
CN Ethanol, 2-[3-[4-amino-5-(3-methoxyphenyl)-5H-pyrrolo[3,2-d]pyrimidin-7-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 201465-22-7 CAPLUS
CN Ethanol, 2-[[2-[3-[4-amino-5-(3-methoxyphenyl)-5H-pyrrolo[3,2-d]pyrimidin-
7-yl]phenoxy]ethyl]amino]- (9CI) (CA INDEX NAME)



RN 201465-23-8 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-(3-methoxyphenyl)-7-[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 201465-24-9 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 201465-25-0 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-(3-methoxyphenyl)-7-[3-[2-(1-piperazinyl)ethoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



L13 ANSWER 1 OF 4 MARPAT COPYRIGHT 2001 ACS
AN 127:108841 MARPAT
TI Preparation of heterocyclyl compounds as drugs
IN Saito, Tsuneo; Takahashi, Toshiya; Kawabe, Norio; Moriya, Yoshiko; Tanaka, Toshiaki
PA Toray Industries, Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09176116	A2	19970708	JP 1995-340181	19951227

PI
GI



I

AB The title compds. (I; A, B, C, D, X = N, C; when X = N, Y = N, C; when X = C, Y = H, C1-4 alkyl, aryl, S, O, etc.; R1 = H, NH2, C1-4 alkyl, OH, etc.; R2-R4 = H, OH, NH2, etc.) are prepd. I are useful as inflammation, allergy, and arthritis inhibitors. Thus, benzo[b]thiophene was reacted with 3,4-dimethoxybenzyl chloride in the presence of zinc chloride and then treated with HBr to give I (A = B = C = D = X = C, Y = S, R1 = R4 = H, R2 = R3 = OH) (II). II showed inhibitory activity for ICAM-1, VCAM-1, IL-1.beta., and 25.8% inhibitory activity for ear edema when tested with mouse.

MSTR 1



G1 = N / 9

G2 = NH2
G4 = 21-22 19-4 21-5



G6 = 29



G7 = Ph
DER: and pharmacologically acceptable salts
MPL: claim 1
NTE: substitution is restricted

L13 ANSWER 2 OF 4 MARPAT COPYRIGHT 2001 ACS
AN 122:105862 MARPAT
TI Preparation and formulation of azaindoles as ulcer inhibitors
IN Takahashi, Toshihiro; Horigome, Masato; Momose, Kenichi; Nagai, Shinji; Oshida, Norio; Sugita, Masanori; Katsuyama, Koichi; Suzuki, Chikako; Nakamaru, Koichi
PA Nisshin Flour Milling Co, Japan
SO Jpn. Kokai Tokkyo Koho, 18 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 06247967	A2	19940906	JP 1993-35268	19930224

GI


I


II

AB The title compds. I [R1 = aryl, etc.; R2 = H; R3 = H, alkyl, etc.; R4 = H, alkyl, alkoxy, etc.; R5 = H, alkoxy, etc.; X, Y, Z = N, C; provisos are given] are prepd. Azaindole deriv. II (prepn. given) in vitro at 10 .mu.g/mL gave 96.2% inhibition of H+, K+-ATPase.

MSTR 1



G4 = pyridyl (SR alkoxycarbonyl<(1-4)>)
G7 = NH2
G9 = 50-2 52-35



G11 = N
DER: and pharmacologically acceptable acid addition salts
MPL: claim 1
NTE: substitution is restricted

L13 ANSWER 3 OF 4 MARPAT COPYRIGHT 2001 ACS
AN 119:226417 MARPAT
TI Preparation of condensed pyrimidinylacyl amino acids as neoplasm inhibitors
IN Akimoto, Hiroshi; Ootsu, Koichiro; Itoh, Fumio
PA Takeda Chemical Industries, Ltd., Japan
SO Eur. Pat. Appl., 51 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 530537	A1	19930310	EP 1992-113523	19920807
	EP 530537	B1	19970108		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	US 5403843	A	19950404	US 1992-926170	19920807
	AT 147386	E	19970115	AT 1992-113523	19920807
	CA 2075787	AA	19930213	CA 1992-2075787	19920811
	JP 06049069	A2	19940222	JP 1992-214142	19920811
PRAI	JP 1991-202042	19910812			
	JP 1992-71513	19920327			
	JP 1992-145851	19920605			

GI For diagram(s), see printed CA Issue.
AB Title compds. [I; ring A = (substituted) (hydrogenated) 5-membered ring; B = (substituted) divalent 5- or 6-membered homo- or heterocyclic group; X = amino, OH, SH; Y = H, halo, C-, N-, O-, or S-bonded group; Z = (substituted) (heteroatom-contg.) divalent group having .ltoreq.5 atoms; W = NRCO; R = H, (substituted) alkyl; R1 = (substituted) cyclic or chain-like group; or RR1 = atoms to form a 3-13 membered ring CO2R2 = optionally esterified carboxyl group; p = 1-4; with provisos], were prepd.
Thus, N.alpha.-[4-[2-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-N.delta.-phthaloyl-L-ornithine Me ester [prepd. by condensation of the corresponding benzoic acid with N.delta.-phthaloyl-L-ornithine Me ester.HCl using di-Et cyanophosphate and Et3N in DMF] was sapond. to give N.alpha.-[4-[2-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-N.delta.-hemiphthaloyl-L-ornithine. This inhibited proliferation of A549 cells with IC50 = 0.0012 .mu.g/mL.

MSTR 1B



G1 = 22-2 20-1 22-10



G2 = Ph (SO (1-3) G3)
G6 = 55



G11 = NH2
DER: or salts
MPL: claim 1
NTE: substitution is restricted

MSTR 2B



G1 = 22-2 20-1 22-10



G2 = Ph (SO (1-3) G3)
G6 = 55



G11 = NH2
DER: or salt reactive derivatives
MPL: claim 72

L13 ANSWER 4 OF 4 MARPAT COPYRIGHT 2001 ACS
AN 118:147575 MARPAT
TI Preparation of (arenopyrimidinylthio)acetates and analogs
IN Gewald, Karl; Schaefer, Harry; Jeschke, Torsten; Eckert, Katrin; Faust, Gottfried; Laban, Gunter
PA Arzneimittelwerk Dresden GmbH, Germany
SO Ger. Offen., 7 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4119767	A1	19921217	DE 1991-4119767	19910615

OS CASREACT 118:147575
GI



I



II



III

AB Title compds. [I; A = atoms to complete a (substituted) arom. or heterocyclic ring; R1 = NH2, OH; R2 = OH, alkoxy; X = Se, S; dashed lined = optional bond] were prepd. by cyclocondensation of acetamidocyclic compds. II (R = halo, Y = cyano, alkoxycarbonyl) with SCN- or SeCN- in the presence of R2H. Thus, 2-(NC)C6H4NHCOCH2Cl was refluxed 3 h with KSCN in EtOH to give 69% title compd. III.

MSTR 1H



G1 = NH2
G6 = 111-6 112-3 113-136



G10 = Ph (SO (1-) G9)
MPL: claim 1

```
=> d l1; d l5; d his
L1 HAS NO ANSWERS
L1                STR
```




```
Structure attributes must be viewed using STN Express query preparation.

L5 HAS NO ANSWERS
L5                STR
```




```
Structure attributes must be viewed using STN Express query preparation.

     (FILE 'MARPAT' ENTERED AT 13:36:59 ON 08 NOV 2001)
                DEL HIS

     FILE 'STNGUIDE' ENTERED AT 13:38:30 ON 08 NOV 2001

     FILE 'REGISTRY' ENTERED AT 13:44:45 ON 08 NOV 2001
L1                STRUCTURE UPLOADED
L2             25 S L1
L3            502 S L1 FUL

     FILE 'CAPLUS' ENTERED AT 13:45:40 ON 08 NOV 2001
L4             99 S L3

     FILE 'REGISTRY' ENTERED AT 13:54:57 ON 08 NOV 2001
L5                STRUCTURE UPLOADED
L6              4 S L5 SAM SUB=L3
L7            106 S L5 FUL SUB=L3

     FILE 'CAPLUS' ENTERED AT 13:55:31 ON 08 NOV 2001
L8              2 S L7

     FILE 'BEILSTEIN' ENTERED AT 13:56:50 ON 08 NOV 2001
L9              0 S L5
L10             0 S L5 FUL

     FILE 'MARPAT' ENTERED AT 13:57:17 ON 08 NOV 2001
L11             0 S L5
L12             6 S L5 FUL
L13             4 S L12 NOT L8
```

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	109.86	932.85

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.24	-61.63

STN INTERNATIONAL LOGOFF AT 13:58:28 ON 08 NOV 2001

```
=> d l1; d his
L1 HAS NO ANSWERS
L1                STR
```



Structure attributes must be viewed using STN Express query preparation.

```
     (FILE 'HOME' ENTERED AT 13:35:42 ON 08 NOV 2001)

     FILE 'REGISTRY' ENTERED AT 13:35:51 ON 08 NOV 2001
L1                STRUCTURE UPLOADED
L2             0 S L1
L3             0 S L1 FUL

     FILE 'BEILSTEIN' ENTERED AT 13:36:34 ON 08 NOV 2001
L4             0 S L1
L5             0 S L1 FUL

     FILE 'MARPAT' ENTERED AT 13:36:59 ON 08 NOV 2001
L6             0 S L1
L7             0 S L1 FUL

=>
```